Literature DB >> 6301918

Quantitative analysis of mouse mammary tumor virus in milk in two sublines of RIII/AnOk mice with low and high mammary tumor incidence.

M Takahashi, S Saga, S Nagayoshi, M Imai, Y Tsutsui, M Hoshino.   

Abstract

Mammary tumors have ceased to develop in descendants of one female of the RIII/AnOk mouse strain which was brought from the Mouse Colony of Okayama University Medical School in 1975, while descendants of another female of this strain have maintained a high tumor incidence. The former and latter descendants were separated out as RIII/AnOk/2 and RIII/AnOk/1 sublines, respectively. The amount of mouse mammary tumor virus (MMTV) in the milk of individual females in these two sublines was determined by means of a sensitive enzyme immunoassay. No MMTV antigens were detected in 59 milk samples of RIII/AnOk/2 females collected during the 1st to 7th lactation periods. On the other hand, all the milk samples of RIII/AnOk/1 females contained MMTV antigens with concentrations ranging from 9 to 400 micrograms/ml. When RIII/AnOk/2 mice were foster-nursed by RIII/AnOk/1 mothers, the infected RIII/AnOk/2 females produced MMTV in the milk to almost the same degree as did the RIII/AnOk/1 females. No genetic differences between the two sublines were observed by the use of reciprocal skin grafting, tumor transplantation, and analysis of biochemical genetic markers. These results indicate that the arrest of mammary tumor development in the RIII/AnOk/2 subline was due to the disappearance of MMTV in the milk.

Entities:  

Mesh:

Year:  1983        PMID: 6301918

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  2 in total

1.  Unique male mammary tumors developing in the inbred soft-furred field rats Millardia meltada.

Authors:  J Lu; A Aoyama; M Hoshino; K Tsuchiya; O Taguchi; M Matsuyama; A Kojima
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

2.  Characterization of the individual and cross-reactive antigens involved in the anti-tumor immunity induced by use of an H-2K-erbB recombinant gene transfectant.

Authors:  L N Ding; T Yoshida; K Isobe; S M Rahman; F Nagase; T Yokochi; K Kawashima; I Nakashima
Journal:  Jpn J Cancer Res       Date:  1991-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.